false
OasisLMS
Login
Catalog
Kidney Week 2026 Early Program On-Demand - Glomeru ...
Genetics of Focal Segmental Glomerulosclerosis: Th ...
Genetics of Focal Segmental Glomerulosclerosis: The Podocyte and Beyond
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
Dr. Matt Sampson discussed how genomic research can improve diagnosis and treatment of focal segmental glomerulosclerosis (FSGS). Genetic variants range from rare, high-impact Mendelian causes to common risk variants, and identifying them can reveal disease mechanisms as well as guide care. Although the prevalence of monogenic FSGS varies by population, genetic testing can be valuable even when biopsy findings do not appear typical.<br /><br />He highlighted emerging genomically inspired treatments: coenzyme Q supplementation was associated with improvement in several patients with CoQ2-related disease, while a phase 2 trial of a TRPC6 inhibitor showed a possible reduction in proteinuria among adults with FSGS.<br /><br />A health-system biobank study of adults found that about 8% had Mendelian variants and 10% had high-risk APOL1 genotypes. These groups showed faster progression to kidney failure. The study also identified a possible association between single pathogenic MEFV variants and severe glomerular disease, including FSGS. This finding requires further validation; MEFV-directed treatment is not yet established.<br /><br />Sampson concluded that collaboration among researchers and clinicians is essential to connect genetic discoveries with mechanisms, therapies, and responsible genomic care for patients.
Asset Caption
Matt G. Sampson, MD
Meta Tag
Speaker
Matt G. Sampson
Keywords
FSGS
genomic research
genetic variants
Mendelian variants
APOL1
TRPC6 inhibitor
coenzyme Q supplementation
×
Please select your language
1
English